Advertisement

Topics

Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated

12:50 EDT 3 Aug 2017 | Topix

Teva Pharmaceutical Industries Ltd 's earnings report brought mostly bad news for investors, which resulted in an 18-percent plunge in the stock Thursday morning. But not all analysts are ready to throw in the towel, as Credit Suisse's Vamil Divan maintains an Outperform rating on Teva with an unchanged $39 price target.

Original Article: Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated

NEXT ARTICLE

More From BioPortfolio on "Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...